{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:06:23Z","timestamp":1793423183830,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose and method<\/jats:title>\n                <jats:p>Patients on hemodialysis develop carpal tunnel syndrome (CTS) due to an accumulation of dialysis-related \u03b22 microglobulin (\u03b22m) amyloid (DRA). In Japan, dialysis technology has progressed remarkably in the past 40\u00a0years and has increased the time until patients require surgery for CTS. However, unclear is whether the time from the start of hemodialysis to the first surgery for CTS is associated with \u03b22m clearance by the different hemodialysis techniques. Therefore, we retrospectively evaluated \u03b22m clearance, serum \u03b22m levels, and the change in the length of this period in patients across 4 periods according to the year that first surgery for CTS was performed: period 1, 1982\u20131989; period 2, 1990\u20131999; period 3, 2000\u20132009; and period 4, 2010\u20132019.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Result<\/jats:title>\n                <jats:p>A total of 222 patients who met the selection criteria were included. Mean \u03b22m clearance was \u22121.8 \u00b1 16.7% in period 1, and improved to 65.4 \u00b1 8.6% in period 3. Accordingly, the serum \u03b22m value after hemodialysis decreased significantly. The time from the start of hemodialysis to the first surgery for CTS was 12.4 \u00b1 2.9\u00a0years in period 1 but increased to 21.8 \u00b1 6.3\u00a0years in period 3. In multivariable linear regression analysis, the significant factors contributing to \u03b22m clearance were periods 2, 3, and 4. In particular, the relation between removal of \u03b22m and the extension of the dialysis vintage in period 1 and 2 was remarkable compared with periods 3 and 4.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our findings indicate that improvement of \u03b22m clearance via advances in dialysis technology might result in a significant extension in the time between starting HD and the first surgery for CTS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10157-021-02122-8","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T15:07:42Z","timestamp":1629472062000},"page":"68-74","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Dialysis-related carpal tunnel syndrome in the past 40\u00a0years"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7096-5604","authenticated-orcid":false,"given":"Masaki","family":"Hatano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izuru","family":"Kitajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seizo","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Isawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Suwabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Ubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"issue":"1","key":"2122_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/kisup.2015.5","volume":"5","author":"N Hanafusa","year":"2015","unstructured":"Hanafusa N, Nakai S, Iseki K, et al. Japanese society for dialysis therapy renal data registry-a window through which we can view the details of Japanese dialysis population. Kidney Int Suppl. 2015;5(1):15\u201322.","journal-title":"Kidney Int Suppl"},{"key":"2122_CR2","first-page":"185","volume":"53","author":"T Akizawa","year":"2010","unstructured":"Akizawa T. Current status of dialysis therapy and related clinical guidelines in Japan. JMAJ. 2010;53:185\u20137.","journal-title":"JMAJ"},{"issue":"6","key":"2122_CR3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.5414\/CN107686","volume":"81","author":"T Suwabe","year":"2014","unstructured":"Suwabe T, Ubara Y, Inoue M, et al. What can we learn from a patient on dialysis for 42 years? Clin Nephrol. 2014;81(6):427\u201334.","journal-title":"Clin Nephrol"},{"issue":"1","key":"2122_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00774-019-01028-6","volume":"38","author":"A Tagami","year":"2020","unstructured":"Tagami A, Tomita M, Adachi S, et al. Epidemiological survey and risk factor analysis of dialysis-related amyloidosis including destructive spondyloarthropathy, dialysis amyloid arthropathy, and carpal tunnel syndrome. J Bone Miner Metab. 2020;38(1):78\u201385.","journal-title":"J Bone Miner Metab"},{"key":"2122_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2147\/IJNRD.S84784","volume":"9","author":"R Scarpioni","year":"2016","unstructured":"Scarpioni R, Ricardi M, Albertazzi V, et al. Dialysis-related amyloidosis: challenges and solutions. Int J Nephrol Renovasc Dis. 2016;9:319\u201328.","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"3","key":"2122_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0006-291X(85)91948-5","volume":"129","author":"F Gejyo","year":"1985","unstructured":"Gejyo F, Yamada T, Odani S, et al. A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. Biochem Biophys Res Commun. 1985;129(3):701\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"2122_CR7","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/ki.1997.262","volume":"51","author":"M Jadoul","year":"1997","unstructured":"Jadoul M, Garbar C, No\u00ebl H, et al. Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: a prospective post-mortem study. Kidney Int. 1997;51(6):1928\u201332.","journal-title":"Kidney Int"},{"issue":"9","key":"2122_CR8","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJM198602273140920","volume":"314","author":"F Gejyo","year":"1986","unstructured":"Gejyo F, Homma N, Suzuki Y, et al. Serum levels of beta 2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis. N Engl J Med. 1986;314(9):585\u20136.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2122_CR9","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/j.bone.2009.03.655","volume":"45","author":"S Yamamoto","year":"2009","unstructured":"Yamamoto S, Kazama JJ, Narita I, et al. Recent progress in understanding dialysis-related amyloidosis. Bone. 2009;45(Suppl 1):S39-42.","journal-title":"Bone"},{"issue":"6","key":"2122_CR10","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1159\/000169048","volume":"16","author":"C K\u00fcchle","year":"1996","unstructured":"K\u00fcchle C, Fricke H, Held E, et al. High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. Am J Nephrol. 1996;16(6):484\u20138.","journal-title":"Am J Nephrol"},{"issue":"4","key":"2122_CR11","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1038\/ki.1997.431","volume":"52","author":"S Schwalbe","year":"1997","unstructured":"Schwalbe S, Holzhauer M, Schaeffer J, et al. Beta 2-microglobulin associated amyloidosis: a vanishing complication of long-term hemodialysis? Kidney Int. 1997;52(4):1077\u201383.","journal-title":"Kidney Int"},{"issue":"1","key":"2122_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/oxfordjournals.ndt.a027964","volume":"15","author":"W Lornoy","year":"2000","unstructured":"Lornoy W, Becaus I, Billiouw JM, et al. On-line haemodiafiltration. Remarkable removal of beta2-microglobulin Long-term clinical observations. Nephrol Dial Transplant. 2000;15(1):49\u201354.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"2122_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.1744-9987.2012.01143.x","volume":"16","author":"S Nakai","year":"2012","unstructured":"Nakai S, Iseki K, Itami N, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2010). Ther Apher Dial. 2012;16(6):483\u2013521.","journal-title":"Ther Apher Dial"},{"issue":"9","key":"2122_CR14","doi-asserted-by":"publisher","first-page":"CR505","DOI":"10.12659\/MSM.881937","volume":"17","author":"J Kope\u0107","year":"2011","unstructured":"Kope\u0107 J, Gadek A, Drozdz M, et al. Carpal tunnel syndrome in hemodialysis patients as a dialysis-related amyloidosis manifestation\u2013incidence, risk factors and results of surgical treatment. Med Sci Monit. 2011;17(9):CR505\u20139.","journal-title":"Med Sci Monit"},{"issue":"1","key":"2122_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/hdi.12057","volume":"18","author":"H Schiffl","year":"2014","unstructured":"Schiffl H. Impact of advanced dialysis technology on the prevalence of dialysis-related amyloidosis in long-term maintenance dialysis patients. Hemodial Int. 2014;18(1):136\u201341.","journal-title":"Hemodial Int"},{"issue":"4","key":"2122_CR16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/ndt\/gfv276","volume":"31","author":"J Hoshino","year":"2016","unstructured":"Hoshino J, Yamagata K, Nishi S, et al. Significance of the decreased risk of dialysis-related amyloidosis now proven by results from Japanese nationwide surveys in 1998 and 2010. Nephrol Dial Transplant. 2016;31(4):595\u2013602.","journal-title":"Nephrol Dial Transplant"},{"key":"2122_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1159\/000362567","volume":"39","author":"J Hoshino","year":"2014","unstructured":"Hoshino J, Yamagata K, Nishi S, et al. Carpal tunnel surgery as proxy for dialysis-related amyloidosis: results from the Japanese society for dialysis therapy. Am J Nephrol. 2014;39:449\u201358.","journal-title":"Am J Nephrol"},{"issue":"7","key":"2122_CR18","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/nep.13077","volume":"23","author":"S Nishi","year":"2018","unstructured":"Nishi S, Hoshino J, Yamamoto S, et al. A multicenter cross sectional study for bone-articular lesions associated with dialysis related amyloidosis in Japan. Nephrology (Carlton). 2018;23(7):640\u20135.","journal-title":"Nephrology (Carlton)"},{"key":"2122_CR19","doi-asserted-by":"crossref","unstructured":"Nitta K, Goto S, Masakane I, Hanafusa N, Taniguchi M, Hasegawa T,Nakai S, Wada A, Hamano T, Hoshino J, Joki N, Abe M, Yamamoto K, Nakamoto H. The Japanese Society for Dialysis Therapy Renal Data Registry Committee. Annual dialysis data report for 2018, JSDT Renal Data Registry: survey methods, facility data, incidence, prevalence, and mortality. Renal Replacement Therapy, 2020","DOI":"10.1186\/s41100-021-00338-8"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-021-02122-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-021-02122-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-021-02122-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T09:04:02Z","timestamp":1641459842000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-021-02122-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["2122"],"URL":"https:\/\/doi.org\/10.1007\/s10157-021-02122-8","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]},"assertion":[{"value":"12 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interests and no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present report was produced in conformity with the Declaration of Helsinki, and the patients gave written informed consent for their data to be analyzed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of ethics"}}]}}